Performance Characteristics of Galactomannan and β-d-Glucan in High-Risk Liver Transplant Recipients
Authors:
- Nina SinghNSNina Singh
- Drew J. WinstonDWDrew J. Winston
- Ajit P. LimayeALAjit P. Limaye
- Shawn PelletierSPShawn Pelletier
- Nasia SafdarNSNasia Safdar
- Michele I. MorrisMMMichele I. Morris
- Katherine MenesesKMKatherine Meneses
- Ronald W. BusuttilRBRonald W. Busuttil
- Marilyn M. WagenerMWMarilyn M. Wagener
- L. Joseph WheatLWL. Joseph Wheat
- 1 December 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 99 (12) , 2543-2550
Abstract
The utility of Aspergillus galactomannan (GM) and β-D-glucan (BG) in liver transplant recipients remains uncertain. As part of a randomized, double-blind trial of antifungal prophylaxis in liver transplant recipients at risk for invasive fungal infections (IFIs), GM and BG were assessed in 199 patients at baseline (enrollment) and weekly thereafter for the duration of study drug. Receiver operating characteristic (ROC) analysis was used to evaluate the accuracy of these for the diagnosis of IFIs. Overall, 46.4% of the patients at baseline had positive GM (index ≥ 0.5) and 89.6% had BG of 80 pg/mL or greater with BG level of 500 pg/mL or greater in 31.8%. Patients with invasive aspergillosis (IA) (3/3) had positive GM at baseline as did 45.5% of those without IA (P = 0.098); the area under the ROC curve for the diagnosis of IA was 0.77 (fair test, ie, good sensitivity but poor specificity). Using BG cutoff of 80 pg/mL or higher, 100% (12/12) of the patients with IFI had positive baseline BG and as did 88.9% (160/180) of those without IFI (P = 0.618); the area under the ROC curve for predicting IFIs was 0.56 (poor test). In multivariate analyses, GM positivity was associated with study site (P = 0.041), and BG positivity with renal replacement therapy (P = 0.05) and study site (P = 0.01). The GM and BG levels declined over time; positivity at subsequent time points was lower in comparison with baseline (P < 0.001). The GM and BG tests had significant center variability and limited accuracy for the diagnosis of IFIs in high-risk liver transplant recipients.Keywords
This publication has 35 references indexed in Scilit:
- Randomized, Double-Blind Trial of Anidulafungin Versus Fluconazole for Prophylaxis of Invasive Fungal Infections in High-Risk Liver Transplant RecipientsAmerican Journal of Transplantation, 2014
- The economic costs to United States hospitals of invasive fungal infections in transplant patientsAmerican Journal of Infection Control, 2011
- Role of (1→3)-β-D-glucan in the diagnosis of invasive aspergillosisMedical Mycology, 2009
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassayEuropean Journal of Clinical Microbiology & Infectious Diseases, 2008
- Diagnosis of Invasive Aspergillosis Using a Galactomannan Assay: A Meta-AnalysisClinical Infectious Diseases, 2006
- Trends in Risk Profiles for and Mortality Associated with Invasive Aspergillosis among Liver Transplant RecipientsClinical Infectious Diseases, 2003
- Risk factors for invasive aspergillosis in liver transplant recipientsLiver Transplantation, 2002
- Prophylactic Fluconazole in Liver Transplant RecipientsAnnals of Internal Medicine, 1999
- RISK FACTORS OF INVASIVE CANDIDA AND NON-CANDIDA FUNGAL INFECTIONS AFTER LIVER TRANSPLANTATION1Transplantation, 1996